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Chronic Kidney Disease: Management of Proteinuria 
Evangelia Maniaki and Natalie Finch 
Introduction 
Chronic kidney disease (CKD) is defined as a chronic sustained reduction in renal function 
and/or structural change. CKD therefore, by this definition, includes patients with 
tubulointerstitial nephritis considered the typical finding in CKD but also patients with 
primary glomerular disease. The distinction between these two is important as they may 
differ in aetiology and also management. In patients with CKD, proteinuria can develop as 
a result of tubular or glomerular injury. In addition, proteinuria may cause renal injury and 
contribute to the progression of CKD. Proteinuria has been associated with all cause 
mortality and hence diagnosis and management is considered important. This article will 
review the pathophysiology of proteinuria in CKD, diagnostic workup and appropriate 
management. 
 
Chronic Kidney Disease 
Chronic Kidney Disease is not a single disease entity, but a heterogeneous syndrome 
caused by a plethora of congenital, familial or acquired factors resulting in loss of 
functioning renal mass. CKD is a significant cause of morbidity and mortality in cats and 
dogs with the UK prevalence reported to be 4% (O′Neill et al., 2013) and 0.37% (O′Neill et 
al., 2014) in the respective populations. Disease prevalence increases with age in both 
species and familial nephropathies are recognised in certain breeds. 
 
Diagnosis and Staging of CKD 
Chronic kidney disease is suspected when consistent historical or clinical findings are 
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present. There should be evidence of disease chronicity, functional and/or structural 
change and/or renal damage. Diagnostic work-up generally involves complete physical 
examination, blood and urine testing as well as imaging. 
Following the diagnosis of CKD, staging is performed. The International Renal Interest 
Society (IRIS) have established a staging system that is applied to patients with normal 
hydration status and stable renal function and is based on fasting serum/plasma creatinine 
concentration (Table 1). 
Table 1: IRIS Staging based on fasting blood creatinine concentration (μmol/l) 
Stage Blood creatinine concentration 
Cats Dogs 
1 <140 <125 
2 140-250 125-180 
3 251-440 181-440 
4 >440 >440 
Substaging is performed for urine protein: creatinine ratio (UPC; Table 2) and systolic 
blood pressure (SBP; Table 3). This is important as proteinuria and hypertension are 
therapeutic targets for which management is aimed at slowing disease progression.  
 
Table 2: IRIS Substaging by Proteinuria (UPC) 
Substage Catsa Dogs 
Non proteinuric <0.2 <0.2 
Borderline proteinuric 0.2-0.4 0.2-0.5 
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Table 2: IRIS Substaging by Proteinuria (UPC) 
Proteinuric >0.4 >0.5 
aNormal intact male cats can have a UPC ≤ 0.6. 
 
Table 3: IRIS Substaging by Systolic Blood Pressure (mmHg) 
Substage Systolic Blood Pressure Risk of Future Target Organ Damage 
Normotensive <150 Minimal 
Borderline 
hypertensive 
150 – 159  Low 
Hypertensive 160 – 179  Moderate 
Severely 
hypertensive 
≥ 180 High 
 
 
Proteinuria in CKD: cause or effect? 
Proteinuria contributes to the progression of CKD by promoting tubulointerstitial 
inflammation, fibrosis and atrophy. Although its role is not fully understood, proteinuria has 
been shown to be a negative prognostic indicator in cats and dogs with CKD and it is 
suggested that it may play a role in disease progression. The mechanisms by which 
proteinuria may cause renal injury have not yet been fully elucidated, but may include 
direct toxicity to tubular cells, inciting inflammatory responses, formation of proteinaceous 
casts resulting in tubular obstruction or it may be the presence of other solutes that are 
filtered through a damaged glomerulus alongside protein that are damaging to the tubules. 
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Glomerular proteinuria 
The functioning unit of the kidney (nephron) consists of the glomerulus with surrounding 
Bowman’s capsule, and renal tubules (Figure 1). The glomerular filtration barrier filters 
water and small solutes from plasma through a pressure driven process. It is charge and 
size selective, thereby restricting the filtration of large (>60KDa) negatively charged 
solutes. The glomerular filtration barrier comprises the fenestrated endothelium, 
glomerular basement membrane and the podocytes. (Figure 2).  
 
As the glomerulus is considered to be the sole filtration barrier to protein, the degree of 
proteinuria is considered to be greater with glomerular injury than tubulointerstitial injury. 
Glomerular proteinuria is often the result of primary glomerular disease. It is generally 
accepted that most dogs with a UPC >2.0 will have glomerular disease, whilst a UPC <2.0 
can be associated with both glomerular and tubulointerstitial disease. Tubulointerstitial 
disease is more closely associated with decreased glomerular filtration rate (GFR). 
Primary glomerular disease is rarely recognised in cats since secondary changes are quite 
common in CKD, especially when hypertension is present. 
 
Tubulointerstitial proteinuria 
Tubulointerstitial proteinuria can develop as a result of defects in protein reabsorption in 
damaged renal tubular cells or a tubulopathy (e.g. Fanconi syndrome) and is also likely to 
be exacerbated by accelerated tubular flow rates. Tubulointerstitial inflammation may 
cause exudation of protein into urine. Tubular damage, tubulointerstitial inflammation and 
fibrosis may also be induced by direct toxicity from filtered proteins.  
Lesions initially localised to one portion of the nephron may result in the formation of 
lesions in other portions and proteinuria itself may contribute to tubulointerstitial disease. 
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Injured tubular cells can lose their capacity to regenerate and, as a result, undergo 
apoptosis. This can lead to tubular atrophy and, consequently, non-functional glomeruli.  
 
 
 
Differentiating glomerular and tubular proteinuria 
The magnitude of proteinuria may be suggestive of whether it is glomerular or tubular in 
origin, but cannot be used definitively. The use of urine electrophoresis to determine the 
presence of low or high molecular weight proteins or a mixed pattern has been suggested 
as a useful method to differentiate between glomerular and tubulointerstitial proteinuria. 
High molecular weight proteinuria may be expected in glomerular damage, whilst low 
molecular weight proteinuria may be expected with tubular damage. In addition, the 
measurement of certain urinary biomarkers such as neutrophil gelatinase-associated 
lipocalin (NGAL) may indicate tubular injury. These methods are largely research tools and 
further research is required to evaluate their clinical utility in proteinuric patients. 
 
Proteinuria in hypertension 
The kidney is susceptible to target organ hypertensive damage. The presence of 
hypertension will result in transmission of high systemic arterial pressure to the 
glomerulus. This in turn will increase hydrostatic pressure at the glomerular filtration 
barrier, resulting in the development of or worsening of pre-existing proteinuria. In addition, 
hypertension can contribute to renal injury.  
 
Management to restore normotension will reduce proteinuria and thus specific therapy for 
proteinuria is not generally required as well. Renin-angiotensin-aldosterone-system 
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(RAAS) inhibition has been shown to cause only a small reduction in blood pressure 
(approximately 15%) and therefore doses in the high end of the dose range may be 
required for the management of hypertensive patients. In canine patients, therapy using 
angiotensin-converting enzyme inhibitors (ACEi) should be initiated if the patient is not 
already receiving this. However, if there is severe hypertension (SBP >200mmHg) or 
evidence of ocular or neurological target organ damage, administration of both an ACEi 
and a second agent is recommended. There are no studies or consensus demonstrating 
the most effective second agent and the authors generally recommend amlodipine. 
However, some clinicians may prefer the use of ARBs. The calcium channel blocker 
amlodipine as a sole agent is the recommended initial therapy of choice for hypertensive 
cats. The goal of treatment should be a SBP between 120-150mmHg in dogs and 120-
160mmHg in cats. 
 
Prevalence of proteinuria in cats and dogs with CKD  
Approximately 20% of cats with CKD will be overtly proteinuric (UPC >0.4). There is less 
data available in dogs that can be used to estimate the prevalence of proteinuria. 
Nevertheless, a higher prevalence than in cats should be expected since primary 
glomerular disease is more common in this species (Jacob et al,2005).  
 
Clinical assessment of proteinuria in cats and dogs with CKD 
Following diagnosis of CKD, an important part of disease staging is to determine if a 
patient is proteinuric. Evaluation of proteinuria includes assessment of its localisation, 
persistence and magnitude.  
 
The localisation of proteinuria can be categorised as pre-renal, renal or post-renal. 
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• Pre-renal proteinuria results from the inability of the tubules to reabsorb the high 
plasma content of small proteins that can freely pass across the glomerular barrier. 
Examples include immunoglobulin light chains in multiple myeloma, myoglobin in 
rhabdomyolysis and haemoglobin in intravascular haemolysis. Serum protein 
electrophoresis or other diagnostics are useful in excluding pre-renal proteinuria. 
• Renal proteinuria results from glomerular or tubulointerstitial pathology as 
discussed above. Functional proteinuria as a result of fever, seizure activity or 
strenuous exercise is possible, although it is rarely recognised in clinical patients. 
• Post-renal proteinuria results from entry of proteins into the urine derived from 
exudative or haemorrhagic processes in the lower urinary tract or genital tract. 
Urine sediment examination should be performed to exclude post-renal proteinuria. 
 
Proteinuria is characterised as persistent if confirmed on three or more occasions, two or 
more weeks apart. 
The magnitude of proteinuria can be assessed using quantitative methods to determine 
urine protein concentration.  
 
Diagnostic testing for proteinuria  
Semi-quantitative methods 
• The reagent pad colorimetric method (“Dipstick”) is a widely available simple to 
perform in-house test. However, it is associated with both false positives and false 
negatives in patients with highly concentrated urine, pigmenturia or very acidic or 
alkaline urine and it has poor sensitivity and specificity particularly in the cat. The 
urine dipstick primarily detects albumin in the urine. The sensitivity of conventional 
urine protein dipsticks for albuminuria in canine and feline urine (a trace positive 
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reaction or greater) was 81% and 90%, respectively, but the specificity was only 
48% and 11%(Lyon et al., 2010). 
• The Sulfosalicylic acid turbidimetric method (SSA) is more reliable than the dipstick, 
however, the sample requires sending to a reference laboratory for analysis. Similar 
to the dipstick test, false positives or negatives can also occur. The SSA test 
detects both albumin and globulin in the urine.  
Both dipstick and SSA results need to be interpreted in the light of USG and sediment 
examination. 
Quantitative methods 
• UPC is considered the most clinically appropriate method for quantification of 
proteinuria and should be performed in any patient with a positive dipstick or SSA or 
when investigating renal proteinuria. Both in-house testing and analysis at reference 
laboratories are available. A single UPC measurement (spot sample) measured 
from either a free catch or cystocentesis sample correlates with 24-hour urine 
quantification in both cats (Adams et al., 1992) and dogs (Grauer et al, 1985). There 
is also excellent correlation between free catch and samples obtained via 
cystocentesis in both cats and dogs (Vilhena et al., 2015; Beatrice et al., 2010). 
Measuring UPC in a pooled sample from 2-3 urine collections is a reliable and cost-
effective alternative to assessing 2-3 serial UPC, but cannot be used for 
demonstrating persistence (LeVine et al, 2010). A normal dog, female cat or 
neutered male cat would be expected to have a UPC <0.2 (see Table 2). However, 
in an intact cat the UPC may be <0.6, most likely due to the presence of urinary 
cauxin. 
• Urine albumin can be measured using a species-specific assay. When performing 
analysis of spot samples, urine albumin can be normalised to a standard USG or, 
more commonly, to creatinine (urine albumin creatinine ratio; UAC). In human 
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patients, microalbuminuria is defined as 30-300mg/day of urinary albumin excretion. 
Microalbuminuria is an important risk factor for cardiovascular disease in humans 
and therefore is routinely measured in many patient groups. However, it does not 
appear to be a similar risk factor in cats and dogs. The clinical benefit of measuring 
urine albumin in cats and dogs remains unclear. Indeed, measurement of UAC 
offered no advantage over UPC in predicting the onset of azotaemic CKD within 12 
months in cats (Jepson et al, 2009). . 
 
Additional screening 
Patients with glomerular level proteinuria should be evaluated to determine if there are any 
potential infectious, inflammatory or neoplastic diseases that may serve as a trigger for 
glomerulonephritis or amyloidosis.  
 
 
 
The renin-angiotensin-aldosterone-system in CKD 
In patients with CKD, there is RAAS activation (Jensen et al, 1997) (Figure 3). Within the 
glomerulus, the effect of this is vasoconstriction of the efferent arteriole with an increase in 
the glomerular capillary hydrostatic pressure. This results in an initial improvement in GFR. 
However, in the long term, RAAS activation is a mediator of progressive renal injury via 
increasing glomerular capillary pressure and associated filtration of plasma proteins. 
RAAS activation and in particular aldosterone are also considered to be important 
mediators of pro-inflammatory and pro-fibrotic pathways.  
 
Passage of proteins across the glomerular filtration barrier is influenced by haemodynamic 
factors and it is thus logical that altering renal haemodynamics should reduce proteinuria. 
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RAAS inhibition has been the main therapeutic target in the approach to reducing 
proteinuria. Agents that target RAAS include ACEi (e.g. benazepril, enalapril), angiotensin-
receptor blockers (ARB; e.g. telmisartan, losartan) and aldosterone-receptor antagonists 
(e.g. spironolactone). Renin inhibitors are used in humans, but have not been used to any 
great extent in dogs or cats.  
 
 
Management of Proteinuria 
Current IRIS guidelines suggest initiating management for persistent proteinuria in cats 
with a UPC >0.4 and dogs with a UPC >0.5. Some clinicians have advocated treatment for 
cats with borderline proteinuria, since these cats have been shown to have a poorer 
prognosis compared to cats with non-proteinuric CKD. 
 
Angiotensin-converting enzyme inhibitors (ACEi) 
The most important mechanism by which ACEi reduce proteinuria is through preferential 
dilation of the efferent arteriole in the glomerulus to decrease glomerular capillary 
hydrostatic pressure. ACEi inhibit the conversion of angiotensin I (AT-I) to angiotensin II 
(AT-II) (Figure 3).  
 
The use of ACEi has been shown to increase survival and delay progression of CKD in 
dogs and humans. Despite a significant reduction in proteinuria, no survival benefit has 
been shown in proteinuric cats, however studies to date have included small numbers of 
patients. In one study, there was no correlation between the intra-renal expression of renin 
and angiotensin II and tubulointerstitial fibrosis in cats, however a positive correlation was 
found in dogs (Mitani et al., 2013). These findings may suggest that intra-renal RAAS 
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activation is not a significant mediator of interstitial fibrosis in cats compared to dogs and 
could explain why ACEi appear to be less effective in cats. 
 
When administered to dogs with glomerulonephritis, enalapril delayed the onset and/or 
progression of azotaemia. Despite this, enalapril is only licensed for the treatment of 
congestive heart failure in dogs and is not licensed in cats in the UK. Benazepril decreases 
proteinuria in both dogs and cats with proteinuric CKD. It is licensed in the UK for the 
management of proteinuric CKD in cats. The authors currently recommend its use only for 
proteinuric (UPC >0.5) patients, however, some clinicians advocate its use in borderline 
proteinuric patients (UPC 0.2-0.5). Benazepril undergoes both renal and hepatic 
elimination, which could offer a potential advantage over enalapril in terms of safety when 
administered to animals with late IRIS stage CKD. There are no other ACEi licensed for 
use in cats and dogs in the UK. Studies evaluating the use of other ACEi such as lisinopril, 
ramipril and imidapril in cats and dogs with proteinuric CKD are lacking (Table 4). There is 
no current evidence to suggest the efficacy of one ACEi to be greater than any other. It is 
likely to be variable between patients due to pharmacodynamic effects and, consequently, 
therapy should be tailored to the individual. 
 
Administration of ACEi can result in hypotension, hyperkalaemia or a decrease in GFR 
that can worsen pre-existing azotaemia. Therefore, patients should be stable, adequately 
hydrated and normotensive prior to initiating ACEi therapy.  
 
Table 4: RAAS inhibitors licensed for the management of proteinuria in CKD in UK 
Class Drug Formulation Licensed 
Indication 
Initial 
dose 
Dose 
adjustments 
Angiotensin- Benazepril Tablet Cats: Reduction of 0.5-1.0 Increase to a 
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Table 4: RAAS inhibitors licensed for the management of proteinuria in CKD in UK 
converting 
enzyme 
inhibitors 
proteinuria 
associated with 
CKD 
 
 
Dogs: Treatment 
of congestive 
heart failure 
 
 
mg/kg PO 
q24hrs 
(C)* 
 
0.25-0.5 
mg/kg PO 
q24hrs 
(D)* 
maximum 
daily dose of 
1mg/kg PO 
q24hrs (D)  
Enalapril Tablet Dogs: Treatment 
of congestive 
heart failure 
0.5 mg/kg 
PO 
q24hrs 
Increase up 
to a 
maximum of 
0.5mg/kg 
q12hrs 
Angiotensin 
receptor 
blockers 
Telmisartan Oral solution Cats: Reduction of 
proteinuria 
associated with 
CKD 
1 mg/kg 
PO 
q24hrs) 
Not 
applicable 
Aldosterone 
receptor 
blockers  
Spironolactone Tablet Dogs: Treatment 
of congestive 
heart failure 
caused by valvular 
regurgitation 
2 mg/kg 
PO q12-
24hrs 
Not 
applicable 
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PO; per os, C; cats, D; dogs, q24hrs; once daily 
* A lower starting dose is recommended in patients with late IRIS stage 3 or stage 4 CKD.  
 
Angiotensin receptor blockers (ARB)  
Most of the functions of AT-II are mediated through the AT-II type-1 receptor (AT1). One of 
the effects of AT-II binding to AT1 includes vasoconstriction and this can exacerbate 
systemic hypertension and proteinuria. The AT-II type-2 receptor (AT2) is considered to 
have renoprotective actions by promoting vasodilation and natriuresis, inhibiting renin 
secretion and exerting anti-inflammatory and anti-fibrotic effects on the kidneys. 
Angiotensin receptor blockers selectively inhibit AT1, preventing AT-II binding. 
 
Several ARB, including telmisartan and losartan (Table 4), have been studied in humans 
with proteinuria and were shown to result in a similar reduction in proteinuria compared to 
ACEi. Losartan was effective in reducing proteinuria in dogs, but not in cats(Jenkins et al, 
2015). However, this study was conducted in response to Angiotensin II infusion and 
therefore may not extrapolate to patients with naturally occurring disease. It is not licensed 
in the UK in either species. Telmisartan is licensed in the UK for reducing proteinuria in 
cats with CKD. The decrease in UPC in cats in which telmisartan was administered 
appeared to be greater than that of benazepril at all assessment points for the 6-month 
duration of a UK study although this did not reach statistical significance. However, there 
was a significant decrease in UPC over time compared to baseline in cats receiving 
telmisartan but not those receiving benazepril (Sent et al, 2015). Studies in humans have 
shown that telmisartan decreased blood pressure as effectively as amlodipine, suggesting 
that it might be the drug of choice for concurrent hypertension and proteinuria. A study in 
healthy cats comparing the administration of benazepril, irbesartan, losartan and various 
doses of telmisartan found that telmisartan had a longer duration of action than benazepril 
and, at a higher dose (3mg/kg), telmisartan attenuated systolic blood pressure to a 
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significantly greater degree than benazepril and all other treatments (Jenkins et al, 2015). 
However, there was no dose escalation of benazepril and therefore with higher doses it is 
possible that this would have also been effective. There are no systematic studies 
evaluating the efficacy of telmisartan administration in dogs with proteinuric CKD, although 
individual reports have been published and there are anecdotal reports of its efficacy. 
 
Aldosterone breakthrough 
Serum aldosterone concentration increases over time in a subset of human patients 
receiving even maximal doses of RAAS inhibitors. This phenomenon is known as 
aldosterone breakthrough. In addition, ACE-escape, in which there is incomplete inhibition 
of conversion of AT-I to AT-II in patients administered ACEi resulting in ongoing AT-II 
production, is also recognised. In humans, the most favoured explanation for aldosterone 
breakthrough and ACE-escape is that non-ACE enzymes such as chymase and cathepsin 
G can cleave ATI to form AT-II. This mechanism for aldosterone breakthrough mediated 
by AT-II might suggest that the phenomenon occurs less often in patients receiving ARBs 
than in those receiving ACEi. However, this does not appear to hold true in human 
patients. The mechanisms of aldosterone breakthrough and ACE-escape in cats and dogs 
are poorly understood and the incidence is unclear. It has been suggested that 
aldosterone breakthrough may develop in up to 33% of dogs with proteinuric renal disease 
receiving RAAS inhibitors (Vaden and Elliott, 2016). Persistently elevated aldosterone 
concentration is of concern as it may have adverse effects on the heart, systemic 
vasculature and kidneys. 
 
Combination therapy 
In human patients, combination therapy with an ACEi and an ARB may be recommended 
if monotherapy is not effective in reducing proteinuria. There are no published studies in 
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cats or dogs evaluating combination therapy. However, it is potentially very dangerous 
given the results of a human study that found increased risk of kidney failure and death in 
elderly patients prescribed combination therapy.  
 
 
Aldosterone receptor antagonists 
Aldosterone receptor antagonists such as spironolactone have been used in humans to 
counter aldosterone breakthrough and also in the management of proteinuric kidney 
disease. There are no published studies exploring the use of aldosterone receptor 
antagonists in dogs or cats with proteinuric CKD. Currently, spironolactone (Table 4) is 
licensed in the UK for the treatment of congestive heart failure in dogs. It may be 
considered in a patient with high serum aldosterone concentration and persistent 
proteinuria despite treatment with ACEi and/or ARB; however, its use would be off license.  
 
Renal Biopsy 
Renal biopsy can potentially provide a definitive diagnosis, but can also provide 
information about the severity of the underlying renal injury. Renal biopsy is indicated in 
patients with suspected glomerular proteinuria of high magnitude (UPC ≥3.5 in dogs) that 
have not responded to standard therapy, such as RAAS inhibition, and that do not have 
any contraindications to a renal biopsy being performed. Such contraindications include 
moderate or marked azotaemia, uncontrolled hypertension, renal cystic disease, 
hydronephrosis, pyelonephritis, coagulopathy or severe anaemia. Renal biopsy is 
indicated in similar scenarios in cats, although glomerular-level proteinuria is seen less 
commonly. Furthermore, over 50% of cats with CKD have been shown to have 
tubulointerstitial nephritis (Chakrabarti et al, 2012; DiBartola et al, 1987) for which results 
of a renal biopsy are unlikely to alter long-term management. 
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Renal biopsies should be obtained under sedation or general anaesthesia using 
ultrasound guidance by someone experienced with the procedure and should be handled 
with extreme care to ensure a diagnosis is made. A practical guide to obtaining a renal 
biopsy is beyond the scope of this review article and it is recommended that a veterinary 
nephropathology centre is contacted prior to obtaining a biopsy to ensure the correct 
fixatives can be provided and to provide further instruction regarding collection. Samples 
are obtained from the renal cortex rather than medulla as the cortex contains the glomeruli 
and also there can be damage to large vessels resulting in haemorrhage or infarction if the 
corticomedullary junction is crossed. Samples should be submitted to a veterinary 
nephropathology service to ensure appropriate processing and provide a full diagnosis. A 
regular pathologist will be able to identify diseases such as lymphoma, amyloidosis or 
pyelonephritis. An experienced nephropathologist, however, will visualise the tissue using 
light microscopy and will be able to identify any ultrastructural changes using electron 
microscopy. Immunostaining techniques can also be applied to the sample. The primary 
aim of obtaining a renal biopsy to investigate glomerular disease in dogs is to determine if 
there is an immunopathogenesis present requiring immunosuppressive therapy. This can 
be identified by the finding of electron-dense immune deposits in the subepithelium, 
subendothelium intramembranous or mesangium of the glomerulus when visualising the 
biopsy using electron microscopy or by the presence of positive immunostaining when 
visualised using immunofluorescence microscopy.  
 
Specific treatment can be tailored based on renal biopsy findings. In dogs with glomerular 
disease, consensus guidelines have been produced by IRIS for the management of 
glomerular disease using data obtained from the WSAVA Renal Standardization Project. 
No similar Renal Standardization Projects have been undertaken in cats to date.  
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It is important to consider that the collection of a renal biopsy should only be performed 
when it is believed that the identification of pathological changes may be useful for 
modifying therapeutic options for the patient. However, the risk of the procedure must 
always be weighed up against any potential benefit. 
 
Table 5: Glomerular diseases in dogs and associated findings on renal biopsy 
 Diagnostic findings on renal 
biopsy 
Glomerulopathy 
Amyloidosis Specific findings 
• Green birefringent material 
when stained with Congo red 
and viewed using polarised 
light 
• Fibrillar material present in the 
mesangium and glomerular 
basement membrane using 
electron microscopy 
Non-specific findings 
• Eosinophilic material on 
haematoxylin and eosin 
staining using light microscopy 
n/a 
Immunecomplex 
glomerulonephritis 
Specific findings 
• Electron-dense immune 
deposits in the subepithelium, 
subendothelium 
n/a 
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intramembranous or 
mesangium of the glomerulus 
using electron microscopy 
• Positive immunostaining using 
immunofluorescence 
microscopy 
Non-specific findings 
• Immune complexes detected 
using Masson’s trichrome on 
light microscopy 
• Glomerular basement 
membrane remodelling 
(spikes, holes, double and 
irregular contours) using Jones 
Methenamine silver staining on 
light microscopy 
• Glomerular endocapillary 
hypercellularity using light 
microscopy 
Non-
immunecomplex 
glomerulonephritis  
Specific findings 
• Ruling out of findings 
consistent with 
immunecomplex 
glomerulonephritis using 
electron microscopy and 
immunofluorescence 
• Focal segmental or 
global 
glomerulosclerosis 
• Glomerular basement 
membrane 
abnormalities 
• Glomerular lipidosis 
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Non-specific findings 
• Smooth contours of the 
glomerular basement 
membrane using light 
microscopy 
 
Note: Glomeruli that are reported 
to be normal using light and 
electron microscopy and 
immunofluorescence should not 
be considered to have non-
immunecomplex 
glomerulonephritis and an 
alternative cause of the 
proteinuria should be investigated. 
• Congenital or 
developmental 
nephropathies 
 
 
Immunosuppressive therapy 
Immunosuppressive treatment should be reserved for patients in which a renal biopsy has 
been performed and there is evidence of immune-mediated disease. Furthermore, any 
underlying infectious disease should be excluded and underlying disease for which 
immunosuppression would be contraindicated should not be present. There is currently a 
lack of controlled clinical trials evaluating immunosuppressive therapies in glomerular 
disease in dogs and this makes evidence-based recommendations difficult. The 
immunosuppressive agent or agents prescribed are dependent on the severity of disease 
and its progression. IRIS consensus guidelines for the management of confirmed 
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immunecomplex glomerulonephritis have suggested the following agents may be effective 
in dogs with acute or rapidly progressive disease: glucocorticoids, mycophenolate, 
cyclosporine, cyclophosphamide and azathioprine (Table 6). For dogs with stable or slowly 
progressive immunecomplex glomerulonephritis, similar immunosuppressive therapies can 
be prescribed; however, agents with a rapid onset of action may be less important in these 
cases. 
 
Approximately 50% of dogs from which renal biopsies have been evaluated had evidence 
of immunecomplex glomerulonephritis. Therefore, when obtaining a renal biopsy is not 
possible due to contraindications, lack of experienced clinician or owner constraints, 
initiating immunosuppressive therapy may be a consideration as one in two dogs are likely 
to be candidates for this. Nevertheless, the potential benefits and risks should be carefully 
discussed with the owner and, if no response to therapy is seen, it should be discontinued 
after 8-12 weeks. IRIS consensus guidelines for glomerular disease in dogs recommend 
that immunosuppressive therapy should be considered without performing a renal biopsy 
when a patient is markedly azotaemic (IRIS stage 3 or 4 CKD), has rapidly progressive 
azotaemia or severe hypoalbuminaemia (<20g/dL). 
 
It is important to remember that immunosuppressive therapy should be prescribed in 
combination with standard therapy such as RAAS blockade. If considering performing a 
renal biopsy or initiating immunosuppressive therapy it may be worth considering 
consulting a veterinary specialist with an interest in nephrology for advice.  
 
Currently, there is a lack of published literature exploring glomerular disease in cats; 
however, clinically this does not appear to be a common diagnosis. When that occurs, the 
most common underlying diagnosis is membranous nephropathy and, interestingly, a 
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greater proportion of cats will have immune-mediated glomerular disease. Therefore, 
immunecomplex glomerulonephritis is considered to be rare in cats and 
immunosuppressive therapy would not be recommended in the management of a 
proteinuric cat unless there is a biopsy-confirmed immunopathogenesis. 
 
Table 6: Immunosuppressive therapy options in the management of canine 
immunecomplex glomerulonephritis 
Immunosuppressive 
drug 
Advantages Disadvantages Evidence for use 
Glucocorticoids Cheap, readily 
available 
Adverse effects e.g 
polyuria and 
polydipsia, increased 
proteinuria, systemic 
hypertension, 
polyphagia, risk of 
thromboembolism, 
adrenal suppression 
Risk of development 
of infection e.g 
urinary tract infection 
IRIS consensus guidelines 
for glomerular disease 
recommend short-term 
administration in fulminant 
cases requiring immediate 
immunosuppression 
(usually in combination 
with other drugs) or in 
cases of multisystemic 
immune-mediated disease 
Mycophenolate Less toxicity 
e.g 
myelotoxicity, 
hepatotoxicity 
than other 
alkylating 
Adverse effects 
(predominantly 
gastrointestinal) are 
dose-dependent and 
reversible following 
withdrawal 
Single case report 
describing its use in a dog 
with glomerulonephritis of 
unknown pathology 
IRIS consensus guidelines 
for glomerular disease 
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agents, 
rapid onset of 
action 
recommends this as the 
first drug of choice for 
managing dogs with acute 
or rapidly progressive 
glomerular disease 
Cyclosporine Readily 
available 
Expensive 
Adverse effects e.g 
gastrointestinal signs, 
gingival hyperplasia 
Little clinical benefit in a 
randomised controlled 
clinical trial of dogs with 
glomerular disease 
IRIS consensus does not 
currently recommend the 
use of cyclosporine. 
Cyclophosphamide Rapid onset of 
action 
Adverse effects e.g 
gastrointestinal signs, 
myelosuppression, 
haemorrhagic cystitis 
Strict regular 
monitoring required 
IRIS consensus guidelines 
for glomerular disease 
recommends this as a 
drug to consider for 
managing dogs with acute 
or rapidly progressive 
glomerular disease 
Azathioprine Cheap Delayed onset of 
action (2-5 weeks) 
Adverse effects e.g 
gastrointestinal signs, 
myelosuppression, 
hepatotoxicity, acute 
pancreatitis 
IRIS consensus guidelines 
for glomerular disease 
describes uncontrolled 
anecdotal clinical 
experience supporting its 
efficacy usually when 
combined with 
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chlorambucil 
 
 
Adjunctive therapies 
Dietary therapy: Renal diets are protein restricted and the feeding of such diets is 
considered to decrease proteinuria not only through decreasing the amount of protein 
presented to the glomerular filtration barrier, but also through reducing intraglomerular 
capillary pressure. However, they are rarely useful as a monotherapy, as they only 
marginally reduce proteinuria. 
 
Omega 3 (n3) and Omega 6 (n6) Polyunsaturated fatty acids (PUFA): Dietary 
supplementation with n3 PUFA decreases the magnitude of proteinuria, whilst 
supplementation with n6 PUFA increases GFR in dogs. The recommended n6/n3 ratio is 
5:1 and this is found in most formulated renal diets. For proteinuric patients that are not fed 
a renal diet, supplementation with n3 PUFA and specifically docosahexaenoic acid and 
eicosapentaenoic acid can be recommended. The dosage is 0.25–0.5g/kg of 
docosahexaenoic acid and eicosapentaenoic acid. In an uncontrolled retrospective study 
evaluating various renal diets fed to cats with CKD, the diet with the highest 
eicosapentaenoic acid (n3) content was associated with the longest survival compared to 
control cats, although all diets studied improved survival. However, a causal relationship 
could not be established and proteinuria was not evaluated. Survival studies in dogs with 
naturally occurring proteinuric CKD receiving PUFA supplementation have not been 
performed. 
 
Antithrombotic therapy: Thromboembolism is recognised in both humans and canine 
proteinuric patients with the prevalence reported to be up to 25% of dogs with glomerular 
  24 
disease. The pathophysiological mechanism remains to be fully elucidated, but factors that 
are likely to be involved include loss of antithrombin into the urine, an increase in plasma 
procoagulant factors and fibrinogen, an increase in platelet reactivity and endothelial 
dysfunction. Unfortunately, there is a lack of evidence for the optimal drug and dosage and 
when to institute prophylactic treatment in dogs. The IRIS consensus guidelines for 
managing canine glomerular disease recommends the administration of low-dose aspirin 
(1-5mg/kg daily) to all dogs with proteinuric glomerular disease, provided that they are 
normotensive and well-hydrated. Clopidrogrel may also be an effective anti-thrombotic 
therapy; however, there is no evidence that it is superior to aspirin and it is significantly 
more expensive.  
 
Thromboembolism is not generally recognised in cats with proteinuric CKD and to the 
authors’ knowledge there are no studies exploring antithrombotic therapy in these patients. 
 
Targets and monitoring of treatment 
The optimal therapeutic target for proteinuric patients receiving standard therapy is to 
decrease UPC to <0.5 in dogs and <0.4 in cats. However, this is not achieved in many 
patients. Serial UPC measurements differ by at least 80% in dogs with low UPC 
(approximately 0.5) and 35% in dogs with high UPC (approximately 12). Therefore, a 
reduction in UPC close to this magnitude is probably required to conclude that treatment is 
effective. The IRIS consensus guidelines for canine glomerular disease recommend a 
reduction in UPC of >50% as an alternative target. Whether achieving any of these 
therapeutic targets offers any survival benefit is still unknown. It is important to note that in 
the later stages of disease when the number of remaining functioning nephrons through 
which protein can be lost has decreased, a decrease in UPC may be seen. 
 
  25 
Following initiation or a change in dose of RAAS blockade therapy, UPC, SBP, serum 
creatinine and potassium should be measured after one to two weeks (see Figure 4). 
Hyperkalaemia can be a common side effect of RAAS inhibition in dogs but not cats with 
CKD. Treatment modification consisting of ACEi or ARB dose reduction, discontinuation of 
spironolactone or feeding a potassium-deficient diet formulated by a veterinary nutritionist, 
is indicated if serum potassium concentrations >6mmol/l are seen. An increase in serum 
creatinine >30% would suggest worsening renal function requiring cessation of treatment 
or a dose reduction. 
 
The IRIS consensus guidelines for monitoring of dogs receiving standard therapy as 
management for glomerular disease recommend measuring UPC, SBP, performing 
biochemistry (to include albumin, creatinine and potassium) and urinalysis at least every 3 
months. This would also be similar to the International Society of Feline Medicine 
consensus guidelines for monitoring of cats with stable CKD. Recommendations for the 
monitoring of dogs receiving immunosuppressive therapy include re-evaluating the 
patients one to two weeks after initiating treatment followed by every two weeks for the 
first 6 weeks and then monthly for three months extending to every 3 months for long term 
monitoring. Evaluation of dogs receiving immunosuppressive therapy should include SBP, 
haematology, biochemistry (to include serum albumin, creatinine, urea, phosphorous, 
electrolytes, hepatic markers and cholesterol), UPC and urinalysis.  
 
Nephrotic syndrome 
Nephrotic syndrome is characterised by the presence of hypoalbuminemia, proteinuria, 
hypercholesterolaemia and fluid accumulation in interstitial spaces and/or body cavities. 
Fluid formation is attributed to decreased plasma colloid osmotic pressure resulting from 
hypoalbuminaemia associated with glomerular protein loss. Intravenous fluid therapy 
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should be administered cautiously to nephrotic patients as they are predisposed to fluid 
overload. Fluid therapy is only indicated for haemodynamic stabilisation. Colloid use may 
be considered when crystalloid fluids alone have not stabilised the patient. Colloids and 
plasma/albumin are only indicated for haemodynamic stabilisation rather than to increase 
oncotic pressure or treat hypoalbuminaemia. The use of diuretics in dogs with oedema 
should be limited to situations where organ function is critically impaired, such as in 
patients with dyspnoea due to pleural effusion. Another indication would be for transient 
reduction in oedema and/or ascites to facilitate renal biopsy. Furosemide is the agent of 
choice in dogs with hyperkalaemia and spironolactone for dogs with pleural or abdominal 
effusion. 
 
Prognosis of cats and dogs with proteinuria associated with CKD 
Proteinuria has been shown to be a negative prognostic indicator in both dogs and cats 
with CKD in multiple studies. In humans and dogs, reducing proteinuria has been shown to 
improve survival, delay disease progression and improve quality of life. In cats, multiple 
studies have concluded that the magnitude of proteinuria is inversely proportional to 
survival and that even mild proteinuria is strongly associated with and predictive of onset 
of azotaemia and progression of CKD. However, a survival benefit has failed to be shown 
in cats receiving therapy to reduce proteinuria. 
Conclusion 
Management of proteinuria is primarily achieved by administering drugs that inhibit the 
RAAS system. Adjunctive treatments such as dietary therapy and n3 PUFA administration 
may also be beneficial in proteinuric patients with CKD. Approximately 50% of dogs with 
glomerular disease may have an immune-mediated pathogenesis and immunosuppressive 
therapies may be indicated in these patients. Management of proteinuria should always be 
tailored to the individual patient and on-going treatment should be based on regular 
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assessment of clinical and laboratory parameters. Reducing proteinuria is an important 
therapeutic target with the aim of delaying progression of CKD and potentially improving 
survival. 
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Figure 1: The structure of the glomerulus. The glomerulus is a network of capillaries 
interposed between the afferent and efferent arterioles enclosed within an epithelial 
capsule (Bowman’s capsule) and separated by the Bowman’s space. Glomerular filtration 
is a pressure-driven process governed by hydrostatic and oncotic pressures in the 
glomerular capillaries and Bowman’s capsule, and by glomerular conductivity and the 
capillary surface area. Taken from Finch, N. (2014). Measurement of glomerular filtration 
rate in cats.Journal of Feline Medicine and Surgery, 16(9), pp.736-748 
 
Figure 2 A (lower magnification) and B (higher magnification): Transmission 
electron micrograph of the glomerular filtration barrier comprising the fenestrated 
endothelial cells, basement membrane and podocytes. P, podocyte; GBM, glomerular 
basement membrane; E, glomerular endothelial cell; FP, podocyte foot process; F, 
glomerular endothelial cell fenestration; SD, podocyte slit diaphragm 
 
Figure 3. The renin-angiotensin-aldosterone-system and its inhibitors. ACE, 
angiotensin-converting enzyme, AT1; angiotensin II type-1 receptor, AT2, angiotensin II 
type-2 receptor. 
• Renin inhibitors are not currently used in cats or dogs 
•  
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• Figure 4. Protocol for adjusting RAAS inhibition therapy in dogs with glomerular 
disease  
• SCr; serum creatinine, K; potassium, BP; blood pressure, UPC; urine: protein 
creatinine ratio 
• *Tolerable limits: SCr change generally considered tolerable in CKD stage 1 or 2 if 
<30% above baseline; in CKD stage 3 <10% but in stage 4 no increase in SCr may be 
tolerable. K tolerable when <6mmol/l. SBP should be ≤160-179mmHg or lower; BP 
decline acceptable if SBP >120mmHg. Adapted from Brown, S., Elliott, J., Francey, T., 
Polzin, D. and Vaden, S. (2013). Consensus Recommendations for Standard Therapy 
of Glomerular Disease in Dogs.Journal of Veterinary Internal Medicine, 27, pp.S27-
S43. 
 
 
